Research Analyst Reaffirms "Buy" Rating on BAT

BusinessBAT by 2FIRSTS.ai

Nov.20.2023

Research Analyst Reaffirms "Buy" Rating on BAT

Research analysts reaffirmed a "buy" rating on British American Tobacco (LON:BATS) after its stock fell 2p (0.02 USD) to 2,518p (30.92 USD) on Wednesday.

In a research report on Wednesday, analysts reconfirmed their "buy" rating on British American Tobacco (LON:BATS). Shares of BATS declined by 2 pence (0.02 USD) to a price of 2,518 pence (30.92 USD) during midday trading on Wednesday.

References:

[1] Jefferies Financial Group Reaffirms Buy Rating for British American Tobacco (LON:BATS)

Also Read:

[1] BAT Celebrating One Year Anniversary of glo™ Smokeless Product

[2] BAT Russian Division's Ownership Transferred to Abu Dhabi

#Research #British American Tobacco (BAT)

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Harm Reduction Experts Warn: FCTC COP11 Policies Risk Marginalizing the Global South

Two global tobacco harm reduction experts, in their submission to 2Firsts, argue that several COP11 policy proposals driven by high-income countries do not align with the capacities and conditions of low- and middle-income countries. They highlight research and funding gaps and call for a more equitable global support mechanism.

Nov.19

Special Report | After the Shortage: How the U.S. Vape Market Is Rebuilding Itself

After a wave of regulatory crackdowns, the U.S. vaping market is undergoing a deep reshuffle — shortages sparked frenzy, and resupply triggered elimination. Through interviews with industry insiders from both China and the United States, 2Firsts reveals how the American market is rebuilding itself amid turbulence.

Nov.12

Russia’s Health Ministry backs full ban on vapes and nalivaykas

Russia’s Ministry of Health (Minzdrav) has expressed support for a full ban on vapes and “nalivayka” alcohol outlets, calling it an effective measure to curb harmful habits and improve public health.

Oct.17 by 2FIRSTS.ai

Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement

President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.